These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 18589476)

  • 41. [Care for HIV/AIDS during parturition].
    Veser T
    Krankenpfl Soins Infirm; 2009; 102(9):24-5. PubMed ID: 19771823
    [No Abstract]   [Full Text] [Related]  

  • 42. Cost-effectiveness of strategies for monitoring the response to antiretroviral therapy in resource-limited settings.
    Phillips AN; Gilks C; Lundgren JD
    Arch Intern Med; 2009 May; 169(9):904; author reply 904-5. PubMed ID: 19433706
    [No Abstract]   [Full Text] [Related]  

  • 43. Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation.
    Kordelas L; Verheyen J; Beelen DW; Horn PA; Heinold A; Kaiser R; Trenschel R; Schadendorf D; Dittmer U; Esser S;
    N Engl J Med; 2014 Aug; 371(9):880-2. PubMed ID: 25162903
    [No Abstract]   [Full Text] [Related]  

  • 44. Who will bridge the HIV treatment-prevention gap?
    Weis P; Schmid G; De Cock K
    J Infect Dis; 2008 Jul; 198(2):293-4. PubMed ID: 18593296
    [No Abstract]   [Full Text] [Related]  

  • 45. CD4 count most cost-effective.
    AIDS Patient Care STDS; 2006 Sep; 20(9):658. PubMed ID: 17039590
    [No Abstract]   [Full Text] [Related]  

  • 46. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
    Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
    AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-HIV agents. Why are drug holidays dangerous?
    TreatmentUpdate; 2009 Jan; 21(1):6-7. PubMed ID: 19248285
    [No Abstract]   [Full Text] [Related]  

  • 48. Self-protection of individual CD4+ T cells against R5 HIV-1 infection by the synthesis of anti-viral CCR5 ligands.
    Guan Y; Abdelwahab S; Kamin-Lewis R; DeVico AL; Lewis GK
    PLoS One; 2008; 3(10):e3481. PubMed ID: 18941536
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The ups and downs of T-cell recovery in HIV-1 disease.
    Rowe PM
    Lancet; 1997 Sep; 350(9079):720. PubMed ID: 9291915
    [No Abstract]   [Full Text] [Related]  

  • 50. Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor.
    Grant P; Taylor J; Cain P; Short W; Gallant J; Farthing C; Thal G; Coakley E; Zolopa A
    Clin Infect Dis; 2009 Mar; 48(5):680-2. PubMed ID: 19191657
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of early initiation of highly active antiretroviral therapy on CD4 cell count and HIV-RNA viral load trends within 24 months of the onset of acute retroviral syndrome.
    Voirin N; Routy JP; Smith D; Baratin D; Trépo C; Cotte L; Touraine JL; Livrozet JM; Cooper DA; Ritter J; André P; Vanhems P
    HIV Med; 2008 Jul; 9(6):440-4. PubMed ID: 18705761
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Better than nothing: keeping pts on failing regimen has benefits.
    Winslow DL
    AIDS Alert; 2009 Apr; 24(4):44-5. PubMed ID: 19382365
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [CCR5 inhibitors. A new point of attack for HIV infection].
    Heinzl S
    Med Monatsschr Pharm; 2007 Dec; 30(12):434-8; quiz 439-40. PubMed ID: 18196845
    [No Abstract]   [Full Text] [Related]  

  • 54. [To finish theoretically with AIDS].
    Nau JY
    Rev Med Suisse; 2008 Dec; 4(183):2705. PubMed ID: 19157288
    [No Abstract]   [Full Text] [Related]  

  • 55. Pakistan starts HIV treatment programme.
    Yusufzai A
    BMJ; 2006 Jan; 332(7532):10. PubMed ID: 16399725
    [No Abstract]   [Full Text] [Related]  

  • 56. Changes in CD4 count with antitubercular therapy in HIV infected children with tuberculosis.
    Mukherjee A; Lodha R; Kabra SK
    J Trop Pediatr; 2009 Apr; 55(2):125-7. PubMed ID: 18829637
    [No Abstract]   [Full Text] [Related]  

  • 57. Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?
    Reekie J; Mocroft A; Sambatakou H; Machala L; Chiesi A; van Lunzen J; Clumeck N; Kirk O; Gazzard B; Lundgren JD;
    AIDS; 2008 Nov; 22(17):2381-90. PubMed ID: 18981778
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Epidemiology, physiopathology and therapeutic modalities of HIV infections].
    Belan AG
    Soins; 2009 Apr; (734):32-5. PubMed ID: 19475824
    [No Abstract]   [Full Text] [Related]  

  • 59. Anti-HIV agents. New evidence changes guidelines about when to start treatment.
    TreatmentUpdate; 2009 Jan; 21(1):2-4. PubMed ID: 19248282
    [No Abstract]   [Full Text] [Related]  

  • 60. [Antiretroviral therapy of HIV infection. German-Austrian guidelines (position in September 2008)].
    ;
    Dtsch Med Wochenschr; 2009 Jan; 134 Suppl 1():S4-15. PubMed ID: 19172554
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.